As of 4:03pm ET
| -0.24 / -0.77%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 32.78, with a high estimate of 50.09 and a low estimate of 25.92. The median estimate represents a +6.05% increase from the last price of 30.91.
The current consensus among 32 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.